STRN and lung adenocarcinoma: Consistent with previous studies, we detected EML4–ALK fusions in ~1% (5/513) of lung adenocarcinoma samples, multiple ALK fusions, including a single STRN–ALK fusion, in thyroid cancer (3/498) and one in papillary renal carcinoma.